SCHEDULE 13G: Oaktree Entities Disclose Significant 22.3% Stake in Oaktree Acquisition Corp. III Life Sciences

A group of Oaktree entities has disclosed a combined beneficial ownership of 22.3% of Oaktree Acquisition Corp. III Life Sciences' Class A ordinary shares, primarily through Class B conversions and private placement securities.

Summary

• Oaktree Acquisition Holdings III LS, LLC, along with its related entities (Holdings GP, OCH, OCGH GP), collectively referred to as the "Reporting Persons," have disclosed beneficial ownership of 5,500,535 Class A ordinary shares of Oaktree Acquisition Corp. III Life Sciences.
• This aggregate ownership represents 22.3% of the issuer's Class A ordinary shares.
• The ownership comprises 4,799,758 Class A ordinary shares convertible from Class B ordinary shares, 583,981 Class A ordinary shares included in private placement units, and 116,796 Class A ordinary shares issuable upon the cash exercise of private placement warrants.
• The Class B ordinary shares are convertible into Class A ordinary shares on a one-for-one basis upon the issuer's initial business combination or earlier at the holder's option.
• The private placement warrants are exercisable at $11.50 per share, become exercisable 30 days after the initial business combination, and expire five years post-combination.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators.

Positives

• The significant stake held by Oaktree entities indicates a strong alignment of interests between the sponsor and the SPAC's future success.
• The substantial ownership percentage (22.3%) suggests a high level of commitment from the Oaktree group to Oaktree Acquisition Corp. III Life Sciences.

Risks

• The value of the Class B ordinary shares and private placement warrants is contingent on the successful completion of an initial business combination, which carries inherent risks associated with SPAC transactions.
• The private placement warrants are subject to an exercise price of $11.50, meaning their value is dependent on the Class A ordinary share price exceeding this threshold post-combination.

Future Outlook

The document indicates that Class B ordinary shares will automatically convert to Class A ordinary shares upon the issuer's initial business combination, and private placement warrants will become exercisable 30 days after this event, expiring five years post-combination. This implies the company's future activities are centered around completing an initial business combination.

Industry Context

Oaktree Acquisition Corp. III Life Sciences is a Special Purpose Acquisition Company (SPAC) sponsored by entities related to Oaktree Capital, a prominent global investment manager. SPACs are formed to raise capital through an initial public offering (IPO) with the purpose of acquiring an existing private company, thereby taking it public. Oaktree's significant ownership stake is typical for a SPAC sponsor, aligning their interests with the successful completion of a de-SPAC transaction in the life sciences sector.

Stakeholder Impact

• Shareholders: The significant ownership by Oaktree entities provides a strong sponsor alignment, which can be viewed positively. However, the Class B shares and warrants represent potential dilution upon conversion/exercise, which is a standard feature of SPACs.
• Management: The Oaktree entities, as significant beneficial owners, likely have substantial influence over the company's strategic direction and the selection of a target for the business combination.

Next Steps

• Completion of an initial business combination by Oaktree Acquisition Corp. III Life Sciences, which would trigger the conversion of Class B shares and exercisability of private placement warrants.

Key Dates

Keywords

Oaktree Acquisition Corp. III Life Sciences, Schedule 13G, Beneficial Ownership, Class A ordinary shares, Class B ordinary shares, Private Placement Units, Private Placement Warrants, SPAC, Special Purpose Acquisition Company, Oaktree Capital, SEC filing, Institutional Ownership